You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

The Prophylactic Use of Filgrastim in Patients with Breast Cancer

Patient Population

Adult patients receiving myelosuppressive chemotherapy for breast cancer.

Research Question(s)

  1. Does the use of filgrastim as primary prophylaxis in patients with early stage (I, II, or III) breast cancer receiving myelosuppressive chemotherapy with curative intent improve clinical outcomes?
  2. Does the use of filgrastim as secondary prophylaxis in patients with early stage (I, II, or III) breast cancer receiving myelosuppressive chemotherapy with curative intent improve clinical outcomes?
  3. Does the use of filgrastim as secondary prophylaxis in patients with advanced stage (IV) breast cancer receiving palliative myelosuppressive chemotherapy after previous dose reduction for neutropenia improve clinical outcomes?

Outcomes of interest include the incidence of febrile neutropenia (FN), death from infection, and maintenance of dose intensity.

pdf download pebcced14-2f.pdf
Modality: 

Supportive Interventions Care

PEBC: 

PEBC

Guideline Identifier: 

CED 14-2

Cancer Continuum: 

Treatment

Cancer Type: 

Breast

Type of Content: 

Guidelines & Advice

Clinical

Authors:  Y. Madarnas A. Eisen R. Myers A.E. Haynes Universal Date:  2009-10-01 00:00:00